Does the liver produce LDL when we eat carbohydrates? What science says and what matters for health

In brief

• The liver synthesizes cholesterol and lipids; excess carbohydrates can increase the production of VLDL, precursors of LDL.
• The role of diet on cholesterol includes complex interactions between carbohydrate type, fats, insulin, and liver metabolism.
• Evidence shows that LDL is an epidemiological risk factor for cardiovascular disease; LDL reduction with statins reduces cardiovascular events.
• Lifestyle changes (physical activity, nutrient choices) are important; supplements and medications have distinct roles and are evaluated by research.

Abstract: what does science say?

Circulating cholesterol travels in the blood within particles called lipoproteins (VLDL, IDL, LDL, HDL). The liver not only processes dietary cholesterol, but also synthesizes it and releases it into circulation by packaging it into VLDL, which, through enzymatic transformations in circulation, can become LDL. Clinical and experimental studies indicate that diets rich in simple carbohydrates or sugars (particularly fructose) and hyperinsulinemia conditions promote de novo hepatic lipogenesis — the conversion of carbohydrates into fatty acids — increasing VLDL secretion and, indirectly, LDL. The evidence is mixed: molecular mechanisms and metabolically controlled studies document the effect of glycemia and insulin on lipogenic pathways; observational studies on food consumption provide variable results regarding clinical risk. The relationship between dietary cholesterol intake (e.g., eggs) and cardiovascular risk is complex and also depends on the dietary context and individual risk factors. Finally, reducing LDL with drugs (statins) has shown a benefit in reducing cardiovascular events in large trials.

What are cholesterol, VLDL, and LDL, and why do they matter?

Cholesterol is a lipid substance essential for cell membranes, the synthesis of steroid hormones, and bile production. In the blood, it is not "free": it is transported within lipoproteins of different densities. The VLDL (very low-density lipoprotein) category is generated in the liver as a vehicle for newly synthesized triglycerides and cholesterol; as VLDLs circulate, they release triglycerides and become denser, eventually becoming LDL (low-density lipoprotein). LDLs are the main carriers of cholesterol to tissues and, when present in excess in the arteries, contribute to the formation of atherosclerotic plaque. The LDL value is therefore a central epidemiological indicator for estimating cardiovascular risk, but it should always be interpreted in conjunction with other factors (age, smoking, blood pressure, diabetes, family history). The physiology of lipid traffic shows that the amount of LDL in the blood does not only depend on how much cholesterol we ingest: it also depends on hepatic production, VLDL assembly, particle conversion, and LDL clearance (uptake) by hepatic receptors. [1]

Why the liver may produce more LDL after excess carbohydrates

The conversion of carbohydrates to fat in the liver, called de novo lipogenesis (DNL), is a biological process documented in human and experimental models. When carbohydrate intake—especially simple sugars and fructose—is high, the liver increases the synthesis of fatty acids, which are esterified into triglycerides and encapsulated in VLDL particles to be exported into the blood. A persistent increase in VLDL production leads to a greater availability of precursors that, through lipolysis and remodeling in circulation, can give rise to IDL and subsequently LDL; in some cases, this leads to an increase in total LDL and the formation of smaller, denser LDL particles, considered more atherogenic. Metabolically controlled studies and observations in people with non-alcoholic fatty liver disease show a significant contribution of DNL to circulating lipid composition: subjects with hepatic fat accumulation exhibit increased rates of lipid synthesis and VLDL production. [2][3][4]

Role of insulin and key enzymes (HMG-CoA reductase, SREBP, ChREBP)

Insulin is a central signal that regulates hepatic metabolism. It stimulates anabolic pathways, including lipogenesis, and can modulate the activity of transcription factors such as SREBP-1c and ChREBP, which increase the expression of enzymes for fatty acid synthesis. The enzyme HMG-CoA reductase is the control point of the cholesterol synthesis pathway in the liver, and its activity is regulated by multiple hormonal and nutritional signals; alterations in post-translational control and genetic regulation can lead to inconsistencies between sterol feedback and actual production. Under conditions of chronic hyperinsulinemia, the stimulation of lipogenic and enzymatic pathways contributes to increasing lipid production and VLDL secretion. [5]

What studies show about carbohydrates, fats, dietary cholesterol, and eggs

Available scientific evidence comes from different types of studies: controlled metabolic experiments, observational population studies, and large clinical trials. Interventions that increase the intake of simple carbohydrates or fructose tend to increase hepatic DNL and blood levels of triglycerides and VLDL in controlled studies; this mechanism has been observed especially when the increase in carbohydrates is associated with caloric surplus or very low-fat diets. [4][3]

Regarding dietary cholesterol (for example, from eggs), analyses of large cohorts have yielded not entirely consistent results: some studies report positive associations between high consumption of cholesterol or eggs and cardiovascular events in certain contexts, while others show no net effect. An analysis of US cohorts highlighted a dose-response association between dietary cholesterol and cardiovascular risk, but the study emphasizes the importance of dietary context and confounding factors. [6]

Finally, it is well-established that industrial trans fats increase cardiovascular risk and worsen the lipid profile; their removal from foods has been an important public health measure. [7] In summary, the effect of diet on plasma cholesterol depends on the overall composition of the diet (type of carbohydrates, quality of fats), energy balance, and individual metabolic conditions.

What it means in practice

For the general public, the practical message is informative, not prescriptive: altered cholesterol levels should be interpreted within the overall context of cardiovascular risk and not as a single parameter. Reducing added sugar intake and limiting foods with trans fats remains a choice with epidemiological and metabolic foundations. Improving carbohydrate quality (preferring whole grains, fresh fruit, vegetables) can mitigate glycemic peaks and the contribution to DNL. Regular physical activity supports lipid metabolism and insulin sensitivity; weight management and blood pressure and smoking control are interventions that reduce risk regardless of a single cholesterol value. Finally, the decision to start medications (statins or others) is clinical and should be personalized: for those with high cardiovascular risk, the benefits of LDL reduction are documented by extensive trials, while in other cases the choice is based on individual factors. [10][12]

Physical Activity, Body Weight, and Lipid Profile Management

Regular physical activity favorably modifies several metabolic indicators: it reduces triglycerides, improves HDL, and can reduce LDL when associated with weight loss or changes in body composition. Recent meta-analyses and network meta-analyses on overweight/obese subjects show that different types of exercise (aerobic, resistance, combined) contribute to improving metabolic markers, including LDL and triglycerides. Exercise acts both by increasing lipid oxidation and by improving insulin sensitivity, thus reducing the drive for hepatic lipogenesis in some subjects. For these reasons, physical activity is a recommended component of interventions for cardiovascular risk control. [9]

Exercise and Lipids: What to Expect

The extent of lipid profile improvement with exercise depends on the intensity, duration, frequency, and initial metabolic status of the person. Even modest reductions in triglycerides and increases in HDL are clinically useful; improvements in LDL are more variable and often related to overall fat mass loss. [9]

Medications, supplements, and what research says

For reducing cardiovascular risk in high-risk individuals, there is strong evidence for the effectiveness of statin therapy: meta-analyses of hundreds of thousands of participants have shown that a 1 mmol/L reduction in LDL is associated with a consistent reduction in vascular events. The decision to start therapy is based on clinical evaluation and risk targets. [10]

Among supplements, coenzyme Q10 has been studied to alleviate muscle symptoms associated with statins; systematic reviews report conflicting results, and the quality of studies remains heterogeneous: some recent meta-analyses suggest a possible reduction in muscle pain, but more robust evidence is needed. [11]

For omega-3 (fish oil), clinical studies and meta-analyses show consistent effects on triglyceride reduction; the translation into a reduction in cardiovascular events has been more heterogeneous and depends on the dose, formulation, and risk profile of the participants. Some large analyses have not found a clear benefit with moderate doses, while trials with high-dose icosapent ethyl have shown reductions in events in selected populations. It is therefore important to evaluate the specific clinical context. [8][12]

How to interpret a lipid profile: values, ratios, and context

A standard report includes total cholesterol, HDL, LDL (direct or calculated), and triglycerides. Interpretation cannot be limited to a single number: it is necessary to assess overall cardiovascular risk. Ratios such as total/HDL or triglycerides/HDL provide additional information. Clinical guidelines recommend classifying risk and establishing lipid targets based on age, comorbidities, history of cardiovascular events, and modifiable factors. For example, in the presence of diabetes, previous coronary artery disease, or high cardiovascular risk, LDL targets are stricter compared to people at low risk. Official recommendations (ESC/EAS and other societies) provide tables and pathways for therapeutic choice and follow-up. [13]

Key points to remember

• The liver synthesizes lipids: an excess of carbohydrates can fuel de novo lipogenesis and increase VLDL production, precursors of LDL.
• Dietary cholesterol contributes to the body's pool, but its effect on blood varies depending on the metabolic context and overall diet.
• Reducing simple carbohydrates, limiting trans fats, and increasing physical activity are evidence-based strategies.
• Statins reduce LDL and cardiovascular events in large trials; pharmacological therapy is a personalized clinical decision.

Limitations of Evidence

It is crucial to distinguish between association and causation: much data comes from observational studies that can be influenced by residual confounding. Controlled metabolic studies show plausible mechanisms (DNL, fructose effects, insulin's role), but their applicability to the general population depends on doses, duration, and energy context. Meta-analyses on supplements (CoQ10, omega-3) report heterogeneous results: dose and population influence outcomes. Finally, individual variability (genetics, microbiota, body composition) modulates dietary and pharmacological responses; therefore, interpretation must be cautious and personalized.

Editorial Conclusion

Contemporary research shows that LDL cholesterol is not merely a direct reflection of dietary cholesterol: hepatic metabolic factors, macronutrient balance, and insulin status play a crucial role. Experimental and clinical evidence confirms that carbohydrate excesses, especially simple sugars and fructose, can stimulate hepatic lipid synthesis and increase VLDL production, with consequent impact on LDL levels. However, clinical management requires a comprehensive assessment of cardiovascular risk and the adoption of multimodal measures: lifestyle modifications, control of risk factors, and, when indicated, pharmacological therapy guided by established guidelines. For individual therapeutic advice or personalized interpretations, consult your trusted physician.

Editorial note

This article is updated and written with attention to source transparency and quality of evidence. The information reported here is for informational and educational purposes only: it does not replace personalized medical advice.

Scientific research

1. Shen WJ, Azhar S, Kraemer FB. The liver at the crossroads: orchestrating lipoprotein dynamics and lipid homeostasis. Annual Review of Physiology. DOI: https://doi.org/10.1146/annurev-physiol-021317-121550. [1]
2. Fabbrini E, Mohammed BS, Magkos F, et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014. DOI: https://doi.org/10.1053/j.gastro.2013.11.049. [2]
3. Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. Journal of Clinical Investigation. 2009. DOI: https://doi.org/10.1172/JCI37385. [3]
4. Hudgins LC, Hellerstein MK, Seidman CE, et al. Effect of high‑carbohydrate feeding on triglyceride and saturated fatty acid synthesis. (Human metabolic studies). DOI: https://doi.org/10.1046/j.1525-1373.2000.22521.x. [4]
5. Goldstein JL, Brown MS. Posttranslational regulation of HMG‑CoA reductase and cholesterol metabolism (review). Annual Review of Biochemistry. 2021. DOI: https://doi.org/10.1146/annurev-biochem-081820-101010. [5]
6. Zhong VW, Van Horn L, Cornelis MC, et al. Associations of dietary cholesterol or egg consumption with incident cardiovascular disease and mortality. JAMA. 2019;321(11):1081–1095. DOI: https://doi.org/10.1001/jama.2019.1572. [6]
7. Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Trans fatty acids and cardiovascular disease. New England Journal of Medicine. 2006. DOI: https://doi.org/10.1056/NEJMra054035. [7]
8. The Effect of Low‑Fat and Low‑Carbohydrate Diets on Weight Loss and Lipid Levels: systematic review and meta‑analysis. Nutrients. 2020. DOI: https://doi.org/10.3390/nu12123774. [8]
9. Liu Y, Wang X, Fang Z. Evaluating the impact of exercise on intermediate disease markers in overweight and obese individuals: network meta‑analysis. Scientific Reports. 2024. DOI: https://doi.org/10.1038/s41598-024-62677-w. [9]
10. Cholesterol Treatment Trialists’ (CTT) Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta‑analysis of individual data from 27 randomized trials. Lancet. 2012. DOI: https://doi.org/10.1016/S0140-6736(12)60367-5. [10]
11. Effects of Coenzyme Q10 on Statin‑Induced Myopathy: Updated Meta‑Analysis. Journal of the American Heart Association. DOI: https://doi.org/10.1161/JAHA.118.009835. [11]
12. Aung T, Halsey J, Kromhout D, et al. Associations of omega‑3 fatty acid supplement use with cardiovascular disease risks: meta‑analysis of 10 trials. JAMA Cardiology. 2018. DOI: https://doi.org/10.1001/jamacardio.2017.5205. [12]
13. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016. DOI: https://doi.org/10.1093/eurheartj/ehw272. [13]